References
- Gurel C, Ozgun M, Batukan C, et al. Prevalence of gestational diabetes among pregnant women attending Erciyes University Medical Faculty. Erciyes Med J 2009;31:323–30
- Ozdemir O, Sari ME, Ertugrul FA, et al. Prevalence of gestational diabetes among pregnant women attending Ankara Numune Training and Research Hospital. Turkey’s Clinics J Gynecol Obst 2014;24:24–9
- Crowther CA, Hiller JE, Moss JR, et al. Effect of treatment of gestational diabetes on pregnancy outcomes. Australian Carbohydrate Intolerance Study in Pregnant Women (ACHOIS) Trial Group. N Engl J Med 2005;352:2477–86
- Thadhani R, Powe CE, Tjoa ML, et al. First trimester follistatin like 3 levels in pregnancies complicated by subsequent gestational diabetes mellitus. Diabetes Care 2010;33:664–9
- Buchanan TA, Xiang A, Kjos SL, et al. What is gestational diabetes? Diabetes Care 2007;30:105–11
- Riskin-Mashiah S, Younes G, Damti A, et al. First-trimester fasting hyperglycemia and adverse pregnancy outcomes. Diabetes Care 2009;32:1639–43
- Williams MA, Qiu C, Muy-Rivera M, et al. Plasma adiponectin concentrations in early pregnancy and subsequent risk of gestational diabetes mellitus. J Clin Endocrinol Metab 2004;89:2306–11
- Spencer K, Yu CKH, Rembouskos G, et al. First trimester sex hormone-binding globulin and subsequent development of preeclampsia or other adverse pregnancy outcomes. Hypertens Pregnancy 2005;24:303–11
- Sidis Y, Mukherjee A, Keutmann H, et al. Biological activity of follistatin isoforms and follistatin-like-3 is dependent on differential cell surface binding and specificity for activin, myostatin, and bone morphogenetic proteins. Endocrinology 2006;147:3586–97
- Flanagan JN, Linder K, Mejhert N, et al. Role of follistatin in promoting adipogenesis in women. J Clin Endocrinol Metab 2009;94:3003–9
- Mukherjee A, Sidis Y, Mahan A, et al. FSTL3 deletion reveals roles for TGF-beta family ligands in glucose and fat homeostasis in adults. Proc Natl Acad Sci USA 2007;104:1348–53
- Hu D, Tian T, Guo J, et al. Decreased maternal and placental concentrations of follistatin-like 3 in gestational diabetes. Clin Chim Acta 2012;413:533–6
- Nanda S, Savvidou M, Syngelaki A, et al. Prediction of gestational diabetes mellitus by maternal factors and biomarkers at 11 to 13 weeks. Prenat Diagn 2011;31:135–14
- American Diabetes Association Position Statement. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010;33:S62–9
- Naf S, Escote X, Ballesteros M, et al. Serum activin A and follistatin levels in gestational diabetes and the association of the activin A-Follistatin system with anthropometric parameters in offspring. PLoS One 2014;9:e92175
- Biron-Shental T, Schaiff WT, Rimon E, et al. Hypoxia enhances the expression of follistatin-like 3 in term human trophoblasts. Placenta 2008;29:51–7
- Petraglia F, De Vita D, Gallinelli A, et al. Abnormal concentration of maternal serum activin-A in gestational diseases. J Clin Endocrinol Metab 1995;80:558–61
- Cash JN, Angerman EB, Keutmann HT, et al. Characterization of follistatin-type domains and their contribution to myostatin and activin A antagonism. Mol Endocrinol 2012;26:1167–78
- Fowler PA, Evans LW, Groome NP, et al. A longitudinal study of maternal serum inhibin-A, inhibin-B, activin-A, activin-AB, pro-alphaC and follistatin during pregnancy. Hum Reprod 1998;13:3530–6